# A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain

> **NCT01719601** · — · WITHDRAWN · sponsor: **Janssen Pharmaceutica**

## Conditions studied

- Moderate to Severe Acute Non-Cancer Pain

## Interventions

- **DRUG:** No intervention

## Key facts

- **NCT ID:** NCT01719601
- **Lead sponsor:** Janssen Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The company decided to cancel this study in conformity with PH FDA Circular 2013-004
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01719601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01719601, "A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01719601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*